Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study
Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile